- Wednesday, 13 September 2017
Biotechnology companies Circa Group Pty. Ltd. and Sanoosa Pty. Ltd. have signed a Memorandum of Understanding (MoU) to continue developing molecules showing early-stage promise in inhibiting protein-protein interactions, which play a key role in disease development.
Targeting such protein complexes directly allows for a more specific response and attacks early disease promoting events.